Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer

Oral contraceptive use is a well-established risk factor for breast cancer and is common among reproductive-aged women in the USA. Its relationship with less common, more aggressive, molecular subtypes is less clear. A population-based case-case analysis was conducted comparing three less common mol...

Full description

Saved in:
Bibliographic Details
Published in:Discover. Oncology 2019-06, Vol.10 (2-3), p.71-76
Main Authors: Lorona, Nicole C., Cook, Linda S., Tang, Mei-Tzu C., Hill, Deirdre A., Wiggins, Charles L., Li, Christopher I.
Format: Article
Language:English
Subjects:
Adult
African Americans
Aged
Body mass index
Breast cancer
Breast Neoplasms - chemically induced
Breast Neoplasms - metabolism
Breast Neoplasms - prevention & control
Cell Biology
Contraceptives, Oral - adverse effects
Data collection
Endocrinology
Estrogens
Female
Gene Expression Regulation, Neoplastic
Hispanic people
Hormone replacement therapy
Humans
Internal Medicine
Medical diagnosis
Medical records
Medicine
Medicine & Public Health
Microbiology
Middle Aged
Odds Ratio
Oncology
Pacific Islander people
Premenopause
Questionnaires
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Regression analysis
Risk Factors
Surveys and Questionnaires
Systems Biology
Triple Negative Breast Neoplasms - chemically induced
Triple Negative Breast Neoplasms - metabolism
Triple Negative Breast Neoplasms - prevention & control
Variables
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oral contraceptive use is a well-established risk factor for breast cancer and is common among reproductive-aged women in the USA. Its relationship with less common, more aggressive, molecular subtypes is less clear. A population-based case-case analysis was conducted comparing three less common molecular subtypes to luminal A breast cancer among 1701 premenopausal cases aged 21–49 diagnosed with a first primary invasive breast cancer between 2004 and 2015. Medical record reviews and structured interviewer-administered questionnaires were used to collect data on oral contraceptive use. Multinomial logistic regression was used to estimate odds ratios (OR) and corresponding 95% confidence intervals (95% CI) for recency of oral contraceptive use for each subtype of breast cancer. Current use of oral contraceptives and use within 5 years before diagnosis was associated with lower odds of H2E tumors compared with luminal A tumors [OR = 0.5, 95% CI: 0.3, 0.9 and OR = 0.5, 95% CI: 0.4, 0.8, respectively] with increasing duration associated with decreasing odds ( p for trend
ISSN:1868-8497
1868-8500
2730-6011
DOI:10.1007/s12672-019-00362-5